natgillin/translations-raw huggingface dataset:
To treat or prevent vomiting, Cerenia tablets should be administered once daily, at a dose of 2 mg maropitant per kg bodyweight, using the number of tablets given in the table below.
Za zdravljenje ali preprečevanje bruhanja dajemo tablete Cerenia enkrat dnevno v odmerku 2 mg maropitanta na kg telesne mase, uporabimo število tablet, kot je navedeno v tabeli.
• For the prevention of nausea induced by chemotherapy.
• Za preprečevanje slabosti, povzročene s kemoterapijo.
Sulphobutyl ether β-cyclodextrin (SBECD) Metacresol
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi Sulfobutil eter β-ciklodekstrin (SBECD)
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
A. IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
Cerenia 10 mg/ml injection for dogs and cats maropitant
Cerenia 10 mg/ml raztopina za injiciranje za pse in mačke maropitant
Maropitant is metabolised in the liver and therefore should be used with caution in dogs with liver disease.
Maropitant se metabolizira v jetrih, zato je potrebna previdna uporaba pri psih z jetrnimi obolenji.
The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 92 ng/ml; this was achieved within 0.75 hours post-dosing (Tmax).
Za farmakokinetični profil maropitanta, danega psom v enkratnem subkutanem odmerku 1 mg/kg telesne mase, je značilna najvišja koncentracija (Cmax) v plazmi okoli 92 ng/ml; ta je dosežena v 0,75 ure po dajanju (tmax).
The pharmacokinetic profile of maropitant when administered as a single oral dose of 2 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 81 ng/ml; this was achieved within 1.9 hours post-dosing (Tmax).
Za farmakokinetični profil maropitanta, danega psom v enkratnem peroralnem odmerku 2 mg/kg telesne mase, je značilna najvišja koncentracija (Cmax) v plazmi okoli 81 ng/ml; ta je dosežena v 1,9 ure po dajanju (Tmax).
EU/2/06/062/005
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/06/062/005
Shelf life after first opening the immediate packaging: 28 days.
Rok uporabnosti zdravila v pakiranju za prodajo: 3 leta Rok uporabnosti po prvem odpiranju stične ovojnine: 28 dni.
The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to cats was characterised by a maximum concentration (Cmax) in plasma of approximately 165 ng/ml; this was achieved on average 0.32 hours (19 min) post-dosing (Tmax).
Za farmakokinetični profil maropitanta, danega mačkam v enkratnem subkutanem odmerku 1 mg/kg telesne mase, je značilna najvišja koncentracija (Cmax) v plazmi okoli 165 ng/ml; ta je dosežena v 0,32 ure po dajanju (tmax).
The safety of the veterinary medicinal product has not been established in dogs less than 16 weeks of age for the 8 mg/kg dose (motion sickness), and in dogs less than 8 weeks of age for the 2 mg/kg dose (vomiting) as well as in pregnant or lactating bitches.
Varnost zdravila v odmerku 8 mg/kg (slabost med vožnjo) pri psih, mlajših od 16 tednov, v odmerku 2 mg/kg (bruhanje) pri psih, mlajših od 8 tednov, ter pri psicah v obdobju brejosti in laktacije ni bila dokazana.
Incidents of pre-travel vomiting, usually within two hours post-dosing were commonly reported after administration of the 8 mg/kg dose.
Po dajanju odmerka 8 mg/kg se je lahko pred vožnjo pojavilo bruhanje, ponavadi v dveh urah po dajanju.
NAME OF MARKETING AUTHORISATION HOLDER
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Maropitant (as maropitant citrate monohydrate)
Zdravilna učinkovina: Maropitant (v obliki maropitantijevega citrata monohidrata) 10 mg.
Cerenia 10 mg/ml solution for injection for dogs and cats
Cerenia 10 mg/ml raztopina za injiciranje za pse in mačke
The safety of the veterinary medicinal product has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and cats.
Varnost zdravila pri psih, mlajših od 8 tednov, pri mačkah, mlajših od 16 tednov, ter pri psicah in mačkah v obdobju brejosti in laktacije ni bila dokazana.
Prevention of motion sickness
Preprečevanje slabosti zaradi vožnje
• For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.
• Za preprečevanje bruhanja, razen bruhanja, ki je posledica slabosti zaradi vožnje.
• For the prevention of vomiting except that induced by motion sickness.
• Za preprečevanje bruhanja razen bruhanja, ki je posledica vožnje
Giving your dog a light meal or snack before administering the tablet could help preventing this effect.
Ta učinek lahko preprečite tako, da psu ponudite manjši obrok ali prigrizek pred aplikacijo tablete.
Prevention of nausea induced by chemotherapy Treatment and prevention of vomiting (except motion sickness) Dog body weight (kg)
Preprečevanje slabosti povzročene s kemoterapijo Zdravljenje ter preprečevanje bruhanja (razen slabosti zaradi vožnje)
Apart from transient reactions at the injection site following subcutaneous administration, Cerenia solution for injection was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5
Z izjemo prehodnih reakcij na mestu injiciranja po subkutanem dajanju, so injiciranje odmerka do 5
AUTHORISATION
FRANCIJA
PACKAGE LEAFLET: Cerenia 10 mg/ml solution for injection for dogs and cats
NAVODILO ZA UPORABO Cerenia 10 mg/ml raztopina za injiciranje za pse in mačke
The safety of Cerenia has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and cats.
Varnost zdravila Cerenia pri psih, mlajših od 8 tednov, mačkah, mlajših od 16 tednov ter pri psicah in mačkah v obdobju brejosti in laktacije ni bila dokazana.
The responsible veterinarian should make a benefit-risk assessment before using Cerenia in dogs under 8 or 16 weeks of age, respectively, or in pregnant or lactating bitches.
Pred uporabo zdravila Cerenia pri psih, mlajših od 8 oziroma 16 tednov ali pri psicah v obdobju brejosti in laktacije, mora odgovorni veterinar oceniti razmerje korist/tveganje.
As maropitant is accumulated in the body during a 14-day treatment period due to metabolic saturation, careful monitoring of liver function in addition to any adverse events should be implemented during long term treatment.
Med dolgotrajnim zdravljenjem je treba skrbno spremljati delovanje jeter in in druge neželene učinke, ker se maropitant zaradi saturacije presnove med 14 dnevnim zdravljenjem, kopiči v telesu.
times the recommended dose) for 15 consecutive days (3-times the recommended duration of administration).
mg/kg (5x večji odmerek od priporočenega) 15 zaporednih dni (3x daljše obdobje od priporočenega) psi in mlade mačke dobro prenašali.
Each tablet contains 24 mg maropitant as maropitant citrate monohydrate.
Tableta vsebuje 24 mg maropitanta v obliki maropitantijevega citrata monohidrata.
The effect duration is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy.
Učinek traja približno 24 ur, zato lahko zdravilo damo večer pred dajanjem zdravila, ki bi lahko povzročilo slabost,
Clinical signs including vomiting on first administration, excess salivation and watery faeces have been observed when the product has been overdosed in excess of 20 mg/kg.
Po dajanju odmerka, ki je presegel 20 mg/kg, so opazili klinične znake, kot so bruhanje po prvem dajanju, prekomerno slinjenje in vodeno blato.
Each tablet contains 16 mg maropitant as maropitant citrate monohydrate.
Tableta vsebuje 16 mg maropitanta v obliki maropitantijevega citrata monohidrata.
Each tablet contains 60 mg maropitant as maropitant citrate monohydrate.
Tableta vsebuje 60 mg maropitanta v obliki maropitantijevega citrata monohidrata.
Each tablet contains 160 mg maropitant as maropitant citrate monohydrate.
Tableta vsebuje 160 mg maropitanta v obliki maropitantijevega citrata monohidrata.
The volume of distribution at steady-state (Vss) was 9.3 l/kg and systemic clearance was 1.5 l/h/kg.
l/kg in sistemski očistek je bil 1,5 l/h/kg.
• For the prevention of vomiting induced by motion sickness.
• Za preprečevanje bruhanja, ki je posledica slabosti zaradi vožnje.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER / Tablets
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Further information on ProZinc can be found on the Agency's website: ema.europe.eu/medicines/veterinary/EPAR/prozinc
Nadaljnje informacije o zdravilu ProZinc so na voljo na spletni strani agencije: ema.europe.eu/medicines/veterinary/EPAR/prozinc
ProZinc (human insulin)
ProZinc (humani insulin)
It is given as an injection under the skin twice daily for cats and once daily for dogs either at the same time or immediately after a meal.
Daje se kot injekcija pod kožo dvakrat na dan pri mačkah in enkrat na dan pri psih hkrati z obrokom ali takoj po njem.
There is a low chance of an allergic reaction in sensitised people.
Pri preobčutljivih ljudeh obstaja majhna verjetnost za alergijsko reakcijo.
It contains the active substance human insulin.
Vsebuje učinkovino humani insulin.
These hypoglycaemic events are generally mild in nature.
Hipoglikemični dogodki so na splošno blagi.
After 12 weeks, 113 out of 134 ProZinc treated dogs (84%) were successfully treated, compared to 91 out of the 111 control dogs (82%).
Po 12 tednih je bilo uspešno zdravljenih 113 od 134 (84 %) psov, v primerjavi z 91 od 111 (82 %) psov v kontrolni skupini.
The correct dose is determined individually for each animal depending on weight and needs to be adjusted depending on the response to treatment.
Pravilen odmerek se določi za vsako žival posebej, odvisno od njene telesne mase, in ga je treba prilagoditi glede na odziv na zdravljenje.
ProZinc received a marketing authorisation valid throughout the EU on 12 July 2013.
Zdravilo ProZinc je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 12. julija 2013.
The European Medicines Agency decided ProZinc's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila ProZinc večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
ProZinc (human insulin) EMA/300817/2013
ProZinc (humani insulin) EMA/300817/2013
Other information about ProZinc
Druge informacije o zdravilu ProZinc
Because of its prolonged action, it must also not be used for the short-term management of diabetic ketoacidosis (a serious complication of diabetes with high levels of ketones in the blood).
Zaradi svojega podaljšanega delovanja se tudi ne sme uporabljati za kratkoročno upravljanje diabetične ketoacidoze (resnega zapleta pri sladkorni bolezni z visoko vsebnostjo ketonov v krvi).
These are absorbed more slowly after injection and take longer to reach their target in the body than naturally produced insulin.
Ti se po injiciranju absorbirajo počasneje in traja dlje, da dosežejo svoj cilj v telesu kot naravno tvorjeni insulin.
Why is ProZinc authorised in the EU?
Zakaj je bilo zdravilo ProZinc odobreno v EU?
ProZinc must not be used in cats or dogs which are hypersensitive (allergic) to insulin or any of the other ingredients.
Zdravilo ProZinc se ne sme uporabljati pri mačkah in psih, ki so preobčutljivi za (alergični na) insulin ali katero koli drugo sestavino zdravila.
What is ProZinc and what is it used for?
Kaj je zdravilo ProZinc in za kaj se uporablja?
An overview of ProZinc and why it is authorised in the EU
Pregled zdravila ProZinc in zakaj je odobreno v EU
What are the risks associated with ProZinc?
Kakšna tveganja so povezana z zdravilom ProZinc?
This results in increased blood glucose levels and associated clinical signs such as polyuria (increase in urine volume), polydipsia (increase in water intake) and weight loss.
Posledica so povečane ravni glukoze v krvi in z njimi povezani klinični znaki, kot so poliurija (povečana količina urina), polidipsija (povečanje vnosa vode) in izguba telesne mase.
ProZinc can only be obtained with a prescription and is available as a suspension for injection (40 IU/ml).
Predpisovanje in izdaja zdravila je le na recept, na voljo pa je v obliki suspenzije za injiciranje (40 i.e./ml).
ProZinc is a veterinary medicine used to treat cats and dogs with diabetes.
ProZinc je zdravilo za uporabo v veterinarski medicini, ki se uporablja za zdravljenje sladkorne bolezni pri mačkah in psih.
For dogs, if there is insufficient response to treatment after 4 - 6 weeks, the dose and/or frequency can be changed.
Pri psih se lahko odmerek in/ali pogostnost dajanja spremenita, če po štirih do šestih tednih ni dovolj odziva na zdravljenje.
The most common side effect during treatment with ProZinc (which may affect more than 1 in 10 animals) is hypoglycaemia (low blood glucose levels) which may result in signs such as hunger, anxiety, unsteady movement, muscle twitching, stumbling or sinking in the rear legs and disorientation.
Najpogostejši neželeni učinek zdravila Procinkov (ki lahko prizadene več kot 1 žival od 10) je hipoglikemija (nizke ravni glukoze v krvi), ki lahko povzroči znake, kot so lakota, anksioznost, nestabilno gibanje, trzanje mišic, spotikanje z zadnjimi nogami ali klecanje zadnjih nog in dezorientacija.
For more information about using ProZinc, see the package leaflet or contact your veterinarian or pharmacist.
Za več informacij glede uporabe zdravila ProZinc glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
In an EU field study involving diabetic dogs, ProZinc was as effective as an authorised veterinary insulin, with improvement of at least one blood sugar measurement and at least one of three clinical signs: bodyweight, polyuria and polydipsia.
V terenski študiji v EU, ki je vključevala pse s sladkorno boleznijo, je bilo zdravilo ProZinc enako učinkovito kot odobreni veterinarski insulin, z izboljšanjem vsaj ene meritve krvnega sladkorja in vsaj enega od treh kliničnih znakov: telesne mase, poliurije in polidipsije.
What benefits of ProZinc have been shown in studies?
Kakšne koristi zdravila ProZinc so se pokazale v študijah?
The active ingredient of ProZinc, human insulin, is produced by a method known as ‘recombinant DNA technology': it is made by yeast cells into which a gene (segment of DNA) has been introduced that makes the yeast cells able to produce insulin.
Učinkovina v zdravilu ProZinc, humani insulin, se proizvaja z metodo, imenovano „tehnologija rekombinantne DNK“, pri kateri ga izdelajo kvasovke, ki so prejele gen (del DNK), kar jim omogoča njegovo tvorjenje.
ProZinc works in the same way as naturally produced insulin with a longer duration of action, and helps glucose enter cells from the blood.
Zdravilo ProZinc deluje enako kot naravno tvorjeni insulin z daljšim trajanjem delovanja in pomaga glukozi pri prehajanju iz krvi v celice.
A glucose containing solution or gel and/or food is required to be given to the animal immediately.
V tem primeru je treba živali takoj dati glukozno raztopino ali gel in/ali hrano.
For a full list of the side effects and restrictions with ProZinc, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila ProZinc glejte navodilo za uporabo.
Diabetes is a disease in which the pancreas does not make enough insulin to control the level of blood glucose (sugar) and/or when the body is unable to use insulin effectively.
Sladkorna bolezen je bolezen, pri kateri trebušna slinavka ne proizvaja dovolj insulina za uravnavanje ravni krvnega sladkorja ali pri kateri telo insulina ne more učinkovito izrabiti.
If the product is accidentally self-injected, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
V primeru nenamernega samoinjiciranja zdravila nemudoma poiščite zdravniško pomoč in zdravniku pokažite navodilo za uporabo ali nalepko.
Accidental self-injection can result in clinical signs of low blood glucose levels which can be treated by taking sugar by mouth.
Nenamerno samoinjiciranje lahko povzroči klinične znake nizkih ravni glukoze v krvi, kar je mogoče odpraviti z peroralnim zaužitjem sladkorja.
ProZinc is an insulin to which protamine and zinc have been added to create crystals.
Zdravilo Prozinc je insulin, ki sta mu bila dodana protamin in cink, da se ustvarijo kristali.
How is ProZinc used?
Kako se zdravilo ProZinc uporablja?
In a field study involving 139 diabetic cats of various ages and breeds, after 6 weeks of treatment with ProZinc average blood sugar levels decreased and clinical signs improved, for example average body weight increased; 116 out of 139 cats (84%) were considered to be treated successfully.
V terenski študiji, ki je vključevala 139 mačk s sladkorno boleznijo različnih starosti in pasem, so se po šestih tednih zdravljenja z zdravilom ProZinc povprečne ravni krvnega sladkorja znižale, klinični znaki
How does ProZinc work?
Kako zdravilo ProZinc deluje?
It should not usually be used on more than one occasion in any one patient.
Navadno se zdravila pri posameznem bolniku ne sme uporabiti več kot enkrat.
The marketing authorisation was renewed on 29 November 2005.
Dovoljenje za promet z zdravilom je bilo podaljšano 29. novembra 2005.
The marketing authorisation holder is CIS bio international.
Imetnik dovoljenja za promet z zdravilom je družba CIS bio international.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NEOSPECT
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) NEOSPECT
This means that it acts like somatostatin, and binds to the same receptors as somatostatin in the body.
To pomeni, da deluje podobno kot somatostatin in se v telesu veže na iste receptorje kot somatostatin.
The European Commission granted a marketing authorisation valid throughout the European Union for NeoSpect on 29 November 2000.
Evropska komisija je dovoljenje za promet z zdravilom NeoSpect, veljavno po vsej Evropski uniji, odobrila dne 29. novembra 2000.
What is the risk associated with NeoSpect?
Kakšna tveganja so povezana z zdravilom NeoSpect?
These receptors are found in large numbers on some malignant tumours such as lung tumours.
Ti receptorji so množično prisotni na nekaterih malignih tumorjih, kot npr. na pljučnih tumorjih.
The main measure of effectiveness was the accuracy of diagnosing a malignant tumour (positive) or a benign tumour (negative).
Glavno merilo učinkovitosti je bila pravilnost diagnosticiranja malignega tumorja (pozitivna vrednost) ali benignega tumorja (negativna vrednost).
NeoSpect should not be used in women who are pregnant
Zdravila NeoSpect ne smejo uporabljati ženske, ki so noseče ali dojijo.
NeoSpect has been studied in two main trials involving 258 patients with suspected lung cancer.
Zdravilo NeoSpect so preučevali v dveh glavnih preizkušanjih, ki sta vključevali 258 bolnikov s sumom na pljučni rak.
NeoSpect is only handled and given by specialised personnel who have experience in the safe handling of radioactive material.
Z zdravilom NeoSpect smejo rokovati in ga dajati le strokovno usposobljene osebe, ki imajo izkušnje z varnim rokovanjem z radioaktivnimi snovmi.
What benefit has NeoSpect shown during the studies?
Kakšne koristi je zdravilo NeoSpect izkazalo med raziskavami?
NeoSpect is not used on its own, but it must be radiolabelled before use.
Zdravilo NeoSpect se ne uporablja samostojno, temveč ga je treba pred uporabo radioaktivno označiti.
The Committee recommended that NeoSpect be given marketing authorisation.
Odbor je zato priporočil, da se za zdravilo NeoSpect odobri dovoljenje za promet z zdravilom.
How has NeoSpect been studied?
Kako je bilo zdravilo NeoSpect raziskano?
The radiolabelled medicine is for diagnostic use.
Radioaktivno označeno zdravilo se uporablja za diagnostične namene.
Side effects with NeoSpect are uncommon, but the most common (seen in between 1 and 10 patients in 1000) are headache, nausea (feeling sick), vomiting, diarrhoea, abdominal (tummy) pain, dizziness, flushing and fatigue (tiredness).
Neželeni učinki zdravila NeoSpect so občasni, vendar pa so najpogostejši (opaženi pri 1 do 10 bolnikih izmed 1000) glavobol, navzeja (slabost), bruhanje, driska, bolečine v trebuhu, omotica,
NeoSpect should not be used in people who may be hypersensitive (allergic) to depreotide, sodium pertechnetate or any of the other ingredients.
Zdravila NeoSpect se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) depreotid, natrijev pertehnetat ali katerokoli drugo sestavino zdravila.
When NeoSpect is radiolabelled, the radioactive element technetium-99m (99mTc) is attached to depreotide.
Z radioaktivno označitvijo zdravila NeoSpect se radioaktivni element tehnecij-99m (99mTc) veže na depreotid.
As depreotide binds to the receptors, it carries the radioactivity with it, and this can be detected using special imaging equipment, such as scintigraphy or single photon emission computed tomography (SPECT).
Ko se depreotid veže na receptorje, s seboj prinese tudi radioaktivnost, to pa je mogoče odkriti s posebno opremo za slikanje, kot je scintigrafija ali računalniška tomografija emisije posameznih fotonov (SPECT).
If it is not, then it is likely to
Če ga ne označi, je le-ta verjetno benigen (nemaligen).
Once made up into a radiolabelled solution, NeoSpect is given by intravenous injection (into a vein), and a scan is taken two to four hours after the injection.
Ko se zdravilo NeoSpect pripravi v obliki radioaktivno označene raztopine, ga vbrizgamo z intravensko injekcijo (v veno), slikanje pa se izvede dve do štiri ure po injiciranju.
The result of the NeoSpect scan was in agreement with the result obtained by histology in between 80 and 90% of the cases.
Rezultat slikanja z uporabo zdravila NeoSpect se je v 80 do 90 % primerov ujemal z rezultatom, dobljenim s histološko preiskavo.
Radiolabelling is a technique where a substance is tagged (labelled) with a radioactive compound.
Radioaktivno označevanje je tehnika, pri kateri se učinkovino označi z radioaktivno spojino.
The active substance in NeoSpect, depreotide, is a somatostatin analogue.
Zdravilna učinkovina zdravila NeoSpect, depreotid, je analog somatostatina.
The Committee for Medicinal products for Human Use (CHMP) decided that NeoSpect's benefits are greater than its risks for the scintigraphic imaging of suspected malignant lung tumours in the lung after initial detection, in combination with CT scan or chest X-ray, in patients with solitary pulmonary nodules.
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila NeoSpect pri scintigrafskem slikanju pljučnih tumorjev s sumom na malignost po začetnem odkritju v kombinaciji z računalniško tomografijo (CT) ali rentgenskim slikanjem prsnega koša pri bolnikih s posameznimi vozliči v pljučih večje od z njim povezanih tveganj.
NeoSpect includes a white powder for solution for injection, which contains the active substance depreotide.
Zdravilo NeoSpect vsebuje bel prašek za pripravo raztopine za injiciranje, ki vsebuje zdravilno učinkovino depreotid.
If the solitary pulmonary nodule is labelled with NeoSpect, it is likely to be malignant.
Če zdravilo NeoSpect označi posamezni pljučni vozlič, je le-ta verjetno maligen.
NeoSpect is radiolabelled by mixing it with a solution of radioactive technetium (99mTc).
Zdravilo NeoSpect se radioaktivno označi tako, da ga zmešamo z raztopino radioaktivnega tehnecija (99mTc).
Adding a NeoSpect scan to a CT scan increased the specificity of the scan, making it easier for the doctor to identify a nodule as malignant.
Dodajanje slikanja z uporabo zdravila NeoScan k računalniški tomografiji (CT) je povečalo specifičnost slikanja in zdravniku olajšalo ugotavljanje malignosti
The full EPAR for NeoSpect is available here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo NeoSpect je na voljo tukaj.
NeoSpect is used in patients who have a single pulmonary nodule (a small, round lesion in the lungs) detected by a chest X-ray or computerised tomography (CT) scan to see if the nodule is malignant (cancerous).
Zdravilo NeoSpect se uporablja pri bolnikih s posameznim vozličem v pljučih (majhno okroglo lezijo v pljučih), ki je bila odkrita z rentgenskim slikanjem prsnega koša ali računalniško tomografijo (CT), da bi ugotovili, ali je vozlič